Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.38 |
| ▸ | LAP3 | P28838 | 3/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15354479 | 1.00 | ALDH1A1 (0.72) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL13822102 | 1.00 | ALDH1A1 (0.72) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL7669784 | 0.86 | ALDH1A1 (0.67) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL7669779 | 0.86 | ALDH1A1 (0.67) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL15810880 | 0.86 | ALDH1A1 (0.67) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Acetylleucine SCHEMBL282371 | 0.84 | ALDH1A1 (1.00) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Levacetylleucine SCHEMBL714003 | 0.84 | ALDH1A1 (1.00) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Levacetylleucine SCHEMBL282372 | 0.84 | ALDH1A1 (1.00) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Levacetylleucine SCHEMBL9438432 | 0.84 | ALDH1A1 (1.00) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL12537181 | 0.82 | ALDH1A1 (0.67) | ALDH1A1MEN1LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-12-14 | — | — | US | disclosed |
| WO-2019021303-A1 | A NOVEL PROCESS FOR THE PREPARATION OF APREMILAST IN AMORPHOUS FORM | ALKEM LABORATORIES LIMITED (IN) | 2019-01-31 | — | — | WO | disclosed |
| US-20170037086-A1 | PEPTIDOMIMETIC MACROCYCLES WITH PTH ACTIVITY | AILERON THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9468625-B2 | Organonitro thioether compounds and medical uses thereof | EPICENTRX, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9321731-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160081981-A1 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF | RADIORX, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160031820-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160030441-A1 | NIACIN MIMETICS, AND METHODS OF USE THEREOF | ARISAPH PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9212142-B2 | Niacin mimetics, and methods of use thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2015-12-15 | — | — | US | disclosed |
| US-9139519-B2 | Organonitro thioether compounds and medical uses thereof | EPICENTRX, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-07 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
| US-20100272681-A1 | Inhibitors of Serine Proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-28 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| WO-2008106139-A1 | INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| EP-0611374-B1 | 17-BETA-SUBSTITUTED 4-AZA-5-ALPHA-ANDROSTAN-3-ONE DERIVATIVES | PHARMACIA & UPJOHN SPA (IT) | 1997-10-22 | — | — | EP | disclosed |
| US-5418238-A | 17β-substituted 4-aza-5α-androstan-3-one derivatives | FARMITALIA CARLO ERBA S.R.L. (IT) | 1995-05-23 | — | — | US | disclosed |
| EP-0611374-A1 | 17-g(b)-SUBSTITUTED 4-AZA-5-g(a)-ANDROSTAN-3-ONE DERIVATIVES. | ERBA FARMITALIA (IT) | 1994-08-24 | — | — | EP | disclosed |
| WO-1994003476-A1 | 17β-SUBSTITUTED 4-AZA-5α-ANDROSTAN-3-ONE DERIVATIVES | FARMITALIA CARLO ERBA S.R.L. (IT) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MPO, MUC1, CRYAB | ALDH1A1 489/4885MEN1 2560/4885LMNA 1643/4885 |
| US-20160030441-A1 | NIACIN MIMETICS, AND METHODS OF USE THEREOF | NAMPT, NNT, NAPRT | ALDH1A1 564/4885MEN1 1859/4885LMNA 1470/4885 |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, PRSS3, PRSS2 | ALDH1A1 1374/4885MEN1 2930/4885LMNA 2814/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | ALDH1A1 1374/4885MEN1 2930/4885LMNA 2814/4885 |
| US-20160081981-A1 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF | SLC22A8, XPOT, NPM1 | ALDH1A1 2447/4885MEN1 218/4885LMNA 4550/4885 |
| US-20100272681-A1 | Inhibitors of Serine Proteases | SERPINB1, PRSS1, SPINT2 | ALDH1A1 2219/4885MEN1 4026/4885LMNA 1534/4885 |
| US-20170037086-A1 | PEPTIDOMIMETIC MACROCYCLES WITH PTH ACTIVITY | PTH1R, CALCA, CALCB | ALDH1A1 4856/4885MEN1 65/4885LMNA 3274/4885 |
| US-20160031820-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | ALDH1A1 1505/4885MEN1 3500/4885LMNA 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.